Compare Stocks: APM, ZIVO, ADIL, and MDCX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$6.65 -6.6%	$4.19	$1.31 ▼ $10.75	$18.70M	1.38	64,222 shs	67,567 shs
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
MDCX Medicus Pharma	$0.17 -1.2%	$0.32	$0.15 ▼ $3.05	$10.87M	0.12	6.69 million shs	22.70 million shs
ZIVO ZIVO Bioscience	$3.11 -13.5%	$4.29	$1.11 ▼ $17.50	$13.12M	0.16	2,997 shs	821 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	+23.83%	+78.89%	+234.27%	-18.28%
APM Aptorum Group	0.00%	0.00%	0.00%	-94.04%	-96.39%
MDCX Medicus Pharma	0.00%	-34.30%	-42.59%	-46.70%	-90.85%
ZIVO ZIVO Bioscience	0.00%	-15.69%	-10.45%	+6.60%	-75.76%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADIL Adial Pharmaceuticals	$6.65 -6.6%	$4.19	$1.31 ▼ $10.75	$18.70M	1.38	64,222 shs	67,567 shs
APM Aptorum Group	$0.67 -4.6%	$5.04	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
MDCX Medicus Pharma	$0.17 -1.2%	$0.32	$0.15 ▼ $3.05	$10.87M	0.12	6.69 million shs	22.70 million shs
ZIVO ZIVO Bioscience	$3.11 -13.5%	$4.29	$1.11 ▼ $17.50	$13.12M	0.16	2,997 shs	821 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADIL Adial Pharmaceuticals	0.00%	+23.83%	+78.89%	+234.27%	-18.28%
APM Aptorum Group	0.00%	0.00%	0.00%	-94.04%	-96.39%
MDCX Medicus Pharma	0.00%	-34.30%	-42.59%	-46.70%	-90.85%
ZIVO ZIVO Bioscience	0.00%	-15.69%	-10.45%	+6.60%	-75.76%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADIL Adial Pharmaceuticals	2.40	Hold	$15.63	134.96% Upside
APM Aptorum Group	1.00	Sell	N/A	N/A
MDCX Medicus Pharma	2.40	Hold	$9.00	5,194.12% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest APM, ZIVO, ADIL, and MDCX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	ADIL Adial Pharmaceuticals	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
7/28/2026	MDCX Medicus Pharma	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/17/2026	ADIL Adial Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	MDCX Medicus Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/29/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/15/2026	ADIL Adial Pharmaceuticals	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
6/15/2026	ADIL Adial Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy
6/11/2026	ADIL Adial Pharmaceuticals	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	$4.75 per share	N/A
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	$15.85K	827.68	N/A	N/A	($0.81) per share	-3.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADIL Adial Pharmaceuticals	-$7.98M	-$14.73	N/A	N/A	N/A	N/A	-203.87%	-512.41%	11/18/2026 (Estimated)
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	-$35.46M	-$2.46	N/A	N/A	N/A	N/A	-3,137.84%	-263.24%	11/13/2026 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$1.40	N/A	N/A	N/A	N/A	N/A	-2,240.92%	N/A

Latest APM, ZIVO, ADIL, and MDCX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	ADIL Adial Pharmaceuticals	-$1.0325	-$11.25	-$10.2175	-$11.25	N/A	N/A
8/12/2026	Q2 2026	MDCX Medicus Pharma	-$0.1275	-$0.21	-$0.0825	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADIL Adial Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADIL Adial Pharmaceuticals	N/A	5.63	5.63
APM Aptorum Group	N/A	0.78	0.78
MDCX Medicus Pharma	N/A	1.57	1.57
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADIL Adial Pharmaceuticals	16.41%
APM Aptorum Group	3.80%
MDCX Medicus Pharma	N/A
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
ADIL Adial Pharmaceuticals	8.00%
APM Aptorum Group	63.99%
MDCX Medicus Pharma	8.10%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADIL Adial Pharmaceuticals	20	2.63 million	2.42 million	No Data
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
MDCX Medicus Pharma	N/A	63.18 million	58.06 million	N/A
ZIVO ZIVO Bioscience	10	4.22 million	2.91 million	Not Optionable

APM, ZIVO, ADIL, and MDCX Headlines

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace

May 12, 2026 | businesswire.com

Zivo Bioscience Inc. Wt

April 11, 2026 | barrons.com

ZIVO Bioscience Provides Special Letter to Shareholders

March 27, 2026 | businesswire.com

Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)

December 15, 2025 | theglobeandmail.com

ZIVO Bioscience releases letter to shareholders

September 14, 2025 | wattagnet.comW

ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses

September 10, 2025 | businesswire.com

ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry

June 20, 2025 | businesswire.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.comM

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.comM

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 1, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, ZIVO, ADIL, and MDCX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

$6.65 -0.47 (-6.60%)

Closing price 04:00 PM Eastern

Extended Trading

$6.55 -0.10 (-1.50%)

As of 07:40 PM Eastern

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Aptorum Group NASDAQ:APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Medicus Pharma NASDAQ:MDCX

$0.17 0.00 (-1.16%)

Closing price 04:00 PM Eastern

Extended Trading

$0.17 +0.00 (+2.35%)

As of 07:59 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

ZIVO Bioscience NASDAQ:ZIVO

$3.11 -0.49 (-13.54%)

As of 02:36 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, ZIVO, ADIL, and MDCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, ZIVO, ADIL, and MDCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, ZIVO, ADIL, and MDCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, ZIVO, ADIL, and MDCX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Aptorum Group NASDAQ:APM

Medicus Pharma NASDAQ:MDCX

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, ZIVO, ADIL, and MDCX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, ZIVO, ADIL, and MDCX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, ZIVO, ADIL, and MDCX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, ZIVO, ADIL, and MDCX Company Descriptions

Adial Pharmaceuticals NASDAQ:ADIL

Aptorum Group NASDAQ:APM

Medicus Pharma NASDAQ:MDCX

ZIVO Bioscience NASDAQ:ZIVO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools